Drugs / LMB-2
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00085150 | Apr 2004 → ? | leukemia, lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00002765 | Apr 1996 → ? | leukemia, lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00924170 | Oct 2008 → Jan 2016 | adult T-cell leukemia/lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00321555 | May 2006 → Aug 2016 | hairy cell leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00295958 | Dec 2005 → Jun 2006 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00080535 | Apr 2004 → Dec 2011 | primary cutaneous T-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00077922 | Feb 2004 → Dec 2011 | lymphoid leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00389506 | Sep 2006 → May 2008 | lymphoma | National Institutes of Health Clinical Center (CC) | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMB-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00080535 ↗ |
| Known as | Anti-Tac(Fv)-PE38 | “The immunotoxin, designed to target CD25(+) malignancies, is composed of the Fv portion of the anti-Tac (anti-CD25) antibody, fused to a 38-kD truncated form of Pseudomonas...” PMID 10552943 ↗ Nov 19994“A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide” NCT00389506 ↗ “A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia” NCT00077922 ↗ “A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas” NCT00080535 ↗ “A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia” NCT00321555 ↗ |
| Action | Deplete | “a toxin produced by bacteria that kills the cancer cells to which it binds” NCT00077922 ↗ |
| Action | Inhibit | “Elongation factor 2 inhibitor” CHEMBL2109367 ↗ |
| Modality | Protein / enzyme biologic | “LMB-2, a recombinant single-chain immunotoxin” NCT00002765 ↗ |
| Route | Intravenous | “LMB-2 at dose levels that ranged from 2 to 63 microg/kg administered intravenously over 30 minutes” PMID 10764422 ↗ Apr 2000 |
| Target | EEF2 | “Elongation factor 2 inhibitor” CHEMBL2109367 ↗ |
| Target | IL2RA | “Interleukin-2 receptor alpha chain binding agent” CHEMBL2109367 ↗ |